Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
315
|
Tue, 7/31/2018,
9:25 AM -
10:10 AM
|
CC-West Hall B
|
|
SPEED: Biopharmaceutical Applications: Trials, Biomarkers, and Enpoint Validation — Contributed Poster Presentations
|
|
Biopharmaceutical Section
|
|
Chair(s): Paul McNicholas, McMaster University
|
|
Oral Presentations
for this session.
|
|
21:
|
Subgroup Mixable Exact Simultaneous Confidence Intervals for Logical Selection of a CDx Cut-Point
Jason Hsu, Ohio State University
|
|
22:
|
A Location-Adjusted Approach to the Covariate-Adjusted Response-Adaptive Allocation Design in Multi-Center Trials
Brian S Di Pace, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; David C. Wheeler, Virginia Commonwealth University
|
|
24:
|
Sample Size Calculation for Pilot Studies
Chi-Hong Tseng, UCLA; Danielle SIM, UCLA
|
|
25:
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
|
|
26:
|
Statistical Considerations for Using Multiple Databases to Build a Biomarker Probability Tool
Feng Gao; Shijia Bian, Biogen; Wenting Wang, Biogen; Nancy Maserejian, Biogen; Judith Jaeger, Albert Einstein College of Medicine; Robert Robert Engle , Biogen; Timothy Swan, Biogen; James McIninch, Alnylam Pharmaceuticals; Feng Gao, Biogen
|
|
28:
|
Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events
Alexia Iasonos, Memorial Sloan Kettering Cancer Center; John O'Quigley, Universit'e Pierre et Marie Curie,
|
|
30:
|
A Bayesian Analysis of Small N Sequential Multiple Assignment Randomized Trials (SnSMARTs)
Boxian Wei, University of Michigan, Ann Arbor; Kelley M Kidwell, University of Michigan; Thomas M Braun, University of Michigan; Roy N Tamura, University of South Florida
|
|
32:
|
Pre-Specified Bias Evaluation of ECG Measurements for Assay Sensitivity Assessment
Xiaoli Hou, Merck; Nancy Kim, Merck; Wei Gao, Merck; Leticia Arrington, Merck; Kajal Larson, Merck
|
|
33:
|
Improvements to the Escalation with Overdose Control Design and a Comparison with the Restricted Continual Reassessment Method
Lingyun Ji, University of Southern California; Richard Sposto, University of Southern California; Juan Pablo Lewinger, University of Southern California; Mark Krailo, University of Southern California; David Conti, University of Southern California; Susan Groshen, University of Southern California; Shahab Asgharzadeh, University of Southern California
|
|
34:
|
Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
|
|
36:
|
Statistical Considerations for Bridging Studies in Precision Medicine Programs with Drug-Device Co-Development
Shunguang Wang, Novartis Analytics; Meijuan Li, FDA; Xiaohong Li, Novartis Analytics; Jincao Wu, CDRH/US. Food and Drug Adminstration; Robinson Douglas, Novartis Pharmaceuticals
|
|
